Ligand Pharmaceuticals (LGND) reported Q4 core adjusted net income Thursday of $1.27 per diluted share, up from $1.05 a year earlier.
Analysts polled by FactSet expected $1.19.
Total revenue for the quarter ended Dec. 31 was $42.8 million, up from $28.1 million a year earlier.
Analysts surveyed by FactSet expected $39 million.
The company expects full year 2025 adjusted earnings in a range of $6.00 to $6.25 per diluted share on total revenue of $180 million to $200 million. Analysts polled by FactSet expect adjusted earnings of $6.07 per diluted share on total revenue of $187.1 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.